A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms

Publisher： John Wiley & Sons Inc

E-ISSN： 1096-8652|93|2|277-285

ISSN： 0361-8609

Source： AMERICAN JOURNAL OF HEMATOLOGY, Vol.93, Iss.2, 2018-02, pp. : 277-285

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase I/II trial of the combination of midostaurin (PKC412) and 5‐azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 4, 2015-04 ,pp. : 276-281

John Wiley & Sons Inc

Access to resources Recommend Favorite

A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011)

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 10, 2015-10 ,pp. : 1717-1724

John Wiley & Sons Inc

Access to resources Recommend Favorite

Spontaneous Remission of Anemia Associated with a Myelodysplastic Syndrome with Disease Evolution into a Myeloproliferative State

By  

Acta Haematologica, Vol. 101, Iss. 1, 1999-03 ,pp. : 50-52

Karger

Access to resources Recommend Favorite

Mixed Myelodysplastic Syndrome and Myeloproliferative Disorder with Bone Marrow and Pulmonary Fibrosis: The Role of Megakaryocytes

By  

Acta Haematologica, Vol. 109, Iss. 3, 2003-05 ,pp. : 145-149

Karger

Access to resources Recommend Favorite

Long‐term outcome of liver transplant patients with Budd‐Chiari syndrome secondary to myeloproliferative neoplasms

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 8, 2015-08 ,pp. : 2042-2049

John Wiley & Sons Inc

Access to resources Recommend Favorite